Summary
In a significant market movement during January 2017, Atlas Genetics was the subject of a vc funding. The transaction achieved a gross valuation of £27,312,142. Leading the round was Wondfo Biotech, BB Biotech Ventures, Novartis Venture Fund, Johnson & Johnson Innovation, Technology Venture Partners, Global Life Science Ventures, RMI Partners.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Wondfo Biotech
Lead Investor / Acquirer
BB Biotech Ventures
Lead Investor / Acquirer
Novartis Venture Fund
Lead Investor / Acquirer
Johnson
Lead Investor / Acquirer
Johnson Innovation
Lead Investor / Acquirer
Technology Venture Partners
Lead Investor / Acquirer
Global Life Science Ventures
Lead Investor / Acquirer
RMI Partners
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Growth prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in